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BACKGROUND
Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcino-
mas, is a heterogeneous disease that consists of various types of renal cancer, 
including tumors with indolent, multifocal presentation and solitary tumors with 
an aggressive, highly lethal phenotype. Little is known about the genetic basis of 
sporadic papillary renal-cell carcinoma, and no effective forms of therapy for ad-
vanced disease exist.
METHODS
We performed comprehensive molecular characterization of 161 primary papillary 
renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, mes-
senger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic 
analysis.
RESULTS
Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types 
of renal cancer characterized by specific genetic alterations, with type 2 further 
classified into three individual subgroups on the basis of molecular differences 
associated with patient survival. Type 1 tumors were associated with MET altera-
tions, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 
mutations, TFE3 fusions, and increased expression of the NRF2–antioxidant re-
sponse element (ARE) pathway. A CpG island methylator phenotype (CIMP) was 
observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was 
characterized by poor survival and mutation of the gene encoding fumarate hydra-
tase (FH).
CONCLUSIONS
Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and 
biologically distinct. Alterations in the MET pathway were associated with type 1, 
and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss 
and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-
cell carcinoma consisted of at least three subtypes based on molecular and pheno-
typic features. (Funded by the National Institutes of Health.)
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Kidney cancer, or renal-cell carci-noma, is not a single disease but is made up of various types of cancer that are 
characterized by different genetic drivers; each 
type has distinct histologic features and a dis-
tinct clinical course and response to therapy.1,2 
Papillary renal-cell carcinoma, which accounts 
for 15 to 20% of kidney cancers, is a heteroge-
neous disease with histologic subtypes and varia-
tions in both disease progression and patient 
outcomes. Papillary renal-cell carcinoma has 
two main subtypes: type 1, which is often multi-
focal, is characterized by papillae and tubular 
structures covered with small cells containing 
basophilic cytoplasm and small, uniform, oval 
nuclei,3 whereas type 2, which is more heteroge-
neous, is characterized by papillae covered with 
large cells containing eosinophilic cytoplasm and 
large, spherical nuclei with prominent nucleoli.3,4 
Although in some patients papillary renal-cell 
carcinoma is indolent, bilateral, and multifocal, 
other patients present with solitary lesions that 
have an aggressive clinical course. Little is known 
about the genetic basis of the sporadic forms of 
papillary renal-cell carcinoma, and there are 
currently no effective forms of therapy for pa-
tients with advanced disease.
Much of our knowledge of the genetic basis 
of papillary renal-cell carcinoma has been based 
on the study of the inherited form of the disease. 
Hereditary papillary renal-cell carcinoma, a rare 
disorder that is associated with an increased risk 
of type 1 disease,4 is characterized by activating 
germline mutations of MET.5 Somatic MET muta-
tions occur in 13 to 15% of nonhereditary papil-
lary renal-cell carcinomas.6,7 The hereditary leio-
myomatosis and renal-cell cancer syndrome, 
which confers a predisposition to an aggressive 
form of type 2 papillary renal-cell carcinoma,8,9 
is caused by germline mutation of the gene en-
coding fumarate hydratase (FH), an enzyme of 
the tricarboxylic acid cycle.10 These aggressive 
tumors are characterized by increased oxidative 
stress11 and activation of the NRF2–antioxidant 
response element (ARE) pathway.12 Mutations in 
the genes that regulate the NRF2-ARE pathway, 
such as CUL3 and NFE2L2 (which encodes NRF2), 
have also been observed in sporadic papillary 
renal-cell carcinoma.13
We performed an integrative genomic analy-
sis of 161 papillary renal-cell carcinoma tumors 
to provide molecular insights into tumor classi-
fication, inform clinical recommendations, and 
suggest paths to the development of mechanisti-
cally based therapies.
Me thods
Patients
Tumors were selected from 161 patients. Patho-
logical review was performed to classify the tu-
mors as type 1, type 2, or uncharacterized papil-
lary renal-cell carcinoma (see the Experimental 
Procedures section in Supplementary Appen-
dix 1, available with the full text of this article 
at NEJM.org). The clinical and genetic character-
istics of these patients are described in Supple-
mentary Appendix 2.
Analytic Platforms
We performed whole-exome sequencing and 
analyses to determine copy number, microRNA 
and messenger RNA (mRNA) expression, protein 
expression, and DNA methylation at CpG sites 
(Supplementary Appendix 3). Details of all the 
analyses are available in the Experimental Proce-
dures section in Supplementary Appendix 1. All 
data sets are available at the Cancer Genome At-
las data portal (https:/ / tcga-data . nci . nih . gov/ tcga).
R esult s
Histologic Subtyping
Pathological review of the 161 tumors identified 
75 type 1 tumors, 60 type 2 tumors, and 26 tu-
mors that could not be classified as type 1 or 
type 2. The type 1 tumors were predominantly 
stage I, whereas the type 2 tumors were fre-
quently stage III or IV (Fig. S1 in Supplementary 
Appendix 1); these findings were consistent with 
those of previous studies.3,14
Role of Somatic Alterations in Molecular 
Differences between Type 1 and Type 2 Tumors
Copy-Number Alterations
Single-nucleotide-polymorphism array–based pro-
filing of somatic copy-number alterations re-
vealed distinctive patterns across three main 
tumor subgroups. One subgroup, composed pre-
dominantly of type 1 and lower-grade tumors, 
was defined by multiple chromosomal gains (of 
at least one complete copy of the chromosome), 
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including nearly universal gain of chromosomes 
7 and 17 and less frequent gain of chromosomes 
2, 3, 12, 16, and 20 (Fig. 1A, and Fig. S2 in 
Supplementary Appendix 1). The other two sub-
groups were predominantly type 2 tumors; 
 although one of these subgroups had few copy-
number alterations, the other was characterized 
by a high degree of aneuploidy with multiple 
chromosomal losses, including frequent loss of 
chromosome 9p, and was associated with poorer 
survival (P<0.001) (Fig. 1A, and Fig. S2 in Sup-
plementary Appendix 1).
Whole-Exome Sequencing
Whole-exome sequencing identified 10,380 puta-
tive somatic mutations in 157 tumors with an 
average of 1.45 nonsilent mutations per mega-
base (see the Experimental Procedures section in 
Supplementary Appendix 1). An initial screen for 
significantly mutated genes with q values of less 
than 0.1 (q values range from 0.0 to 1.0), with 
the use of MutSigCV, version 2.0, identified five 
such genes (MET, SETD2, NF2, KDM6A, and 
SMARCB1) that were recurrently mutated in pap-
illary renal-cell carcinoma, representing 24% of 
cases (Fig. 1B). Further analysis, performed with 
restriction of multiple hypothesis testing to 
genes previously associated with cancer in the 
PanCan21 data set,15 identified six additional 
significantly mutated genes (FAT1, BAP1, PBRM1, 
STAG2, NFE2L2, and TP53), with 36% of cases 
showing mutation of at least one of these genes 
(Fig. 1B). Mutation of these significantly mutat-
ed genes showed no evidence of subclonality 
(Supplementary Appendix 4).
Hippo and Chromatin Modifier Pathways
Several significantly mutated genes in papillary 
renal-cell carcinoma are components of well-
known cancer-associated pathways or complexes, 
including NF2 in the Hippo signaling pathway, 
SMARCB1 and PBRM1 in the SWI/SNF complex, 
and SETD2, KDM6A, and BAP1 in several chroma-
tin modifier pathways. Assessment of genes in 
these pathways (Supplementary Appendix 5) 
showed a high number of mutations in both 
type 1 and type 2 tumors involving the SWI/SNF 
complex (20% and 27%, respectively), chromatin 
modifier pathways (35% and 38%, respectively), 
and the Hippo signaling pathway (3% and 10%, 
respectively) (Fig. 1C).
TFE3 and TFEB Gene Fusions
Gene fusions involving TFE3 or TFEB have previ-
ously been associated with papillary renal-cell 
carcinoma (reviewed in Kauffman et al.16). We 
identified gene fusions in 17 tumors (10.6%), 
including 8 involving TFE3 or TFEB (Supplemen-
tary Appendix 6). Four of the TFE3 fusions in-
volved known fusion partners, PRCC and SFPQ, 
and 2 involved novel fusion partners, RBM10 and 
DVL2 (Fig. 1D). The tumors with TFE3 fusions 
showed varying degrees of increased mRNA ex-
pression for known TFE3 transcriptional targets, 
including CTSK, BIRC7, DIAPH1, and HIF1A (Fig. 
S3 in Supplementary Appendix 1). The two TFEB 
fusions involved novel fusion partners, COL21A1 
and CADM2, with the COL21A1–TFEB fusion re-
sulting in a construct similar to the known 
MALAT1–TFEB fusions16 and the TFEB–CADM2 
fusion resulting in a novel truncated version of 
TFEB that had lost several microRNA binding 
sites (Fig. 1D). The tumors with TFEB fusions 
showed high mRNA expression of the TFEB tran-
scription factor and a known target gene, CTSK 
(Fig. S4 in Supplementary Appendix 1). Seven of 
the fusions involving TFE3 or TFEB were identi-
fied in the type 2 tumors (7 of 60 [12%]).
Alterations Specific to Types of Papillary 
Renal-Cell Carcinoma
MET Mutation in Type 1 Tumors
We found mutation of MET in 17 tumors, includ-
ing germline mutation in 3 tumors. A total of 
14 of the 17 MET mutations were in the tyrosine 
kinase domain, and 13 of these mutations were 
observed in type 1 tumors (17% of the 75 type 1 
tumors) (Fig. 2A and 2B). In addition, an alter-
nate MET RNA transcript that replaces canonical 
exons 1 and 2 with a novel exon 1 spliced to 
canonical exon 3 (Fig. 2A) was identified in 
8 tumors (4 type 1 tumors, 3 type 2 tumors, and 
1 unclassified tumor). This isoform represented 
the majority of transcripts in 2 tumors and a 
fraction in the remaining 6 tumors and was re-
cently observed to produce a stable, shortened 
protein in gastric-cancer cell lines (Fig. S5A in 
Supplementary Appendix 1).19 Exons 1 and 2 of 
MET encode the ligand-binding domain of hepa-
tocyte growth factor receptor; this isoform, 
analogous to the epidermal growth factor recep-
tor variant III isoform,20 may result in ligand-
independent MET activation. In addition, gene 
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fusions involving MET were observed in 3 tumors 
(Supplementary Appendix 6). Levels of MET
mRNA expression and of protein phosphoryla-
tion (pY1235) were significantly higher in type 1 
tumors than in type 2 tumors (P<1×10−9 and 
P = 0.007, respectively, by t-test) (Fig. S5B in 
Supplementary Appendix 1) — a finding poten-
tially driven in part by trisomy of chromosome 7 
in type 1 tumors. Altered MET status (defined as 
mutation, splice variant, or gene fusion) or in-
creased chromosome 7 copy number (which en-
codes MET but may also involve other genes) was 
identified in 81% of type 1 papillary renal-cell 
carcinomas. Analysis by means of Genomic 
Identification of Significant Targets in Cancer 
(GISTIC), version 2.0, determined that the loss of 
1p36 observed in 18 papillary renal-cell carcino-
mas (11.2%) included the candidate tumor sup-
pressor ERRFI1, a negative regulator of EGFR
Figure 1 (facing page). Somatic Alterations in Papillary 
Renal-Cell Carcinoma and Molecular Differences 
 between Type 1 and Type 2 Cancers.
Unsupervised clustering of DNA copy profiles of 161 
papillary renal-cell carcinomas (PRCCs) (Panel A) re-
vealed three molecular subtypes, one of which was 
highly enriched for type 1 tumors and the other two 
for type 2 tumors. SCNA denotes somatic copy-number 
alterations. Significantly mutated genes (SMGs) in PRCC 
(Panel B) were determined by considering all genes 
(q<0.1 [range, 0.0 to 1.0]) or focusing on the set of 260 
genes previously implicated in cancer by large-scale, 
pan-cancer exome analyses15 (q<0.1). P values were 
calculated with the MutSigCV algorithm, version 2.0. 
A pathway-centric view of gene mutations in PRCC 
(Panel C) shows key pathways and genes implicated 
in cancer, either in the current study or elsewhere.15 
The tumors were classified according to histologic type 
(from left to right) and according to gene or pathway 
altered (from top to bottom). Pathways and genes 
 represented include MET, the Hippo pathway (NF2, 
SAV1, and WWC1), the NRF2 pathway (NFE2L2, KEAP1, 
CUL3, SIRT1, and FH), chromatin modification 
(CREBBP, DOTL1, EHMT1/2, EP300, EZH1/2, KAT2A/B, 
KDM1A/B, KDM4A/B, KDM5A/B/C, KDM6A/B, 
MLL1/2/3/4/5, NSD1, SETD2, SMYD4, and SRCAP), 
the SWI/SNF complex (ACTB, ACTL6A/B, ARID1A/B, 
ARID2, BCL6A/B/C, BCL11A/B, BRD7/9, DPF1/2/3, 
PHF10, PBRM1, SMARCA2/4, SMARCB1, SMARCC1/2, 
SMARCD1/2/3, and SMARCE1), the mammalian target 
of rapamycin (mTOR) pathway (MTOR, PIK3CA, PTEN, 
STK11, TSC1, and TSC2), and the p53 pathway (ATM, 
CDKN1A,  CDKN2A, FBXW7, RB1, and TP53). Fusion 
gene analysis (Panel D) identified TFE3 or TFEB fusions 
in eight PRCC tumors, including two novel gene-fusion 
partners for TFE3 (DVL2 and RBM10) and two novel 
gene-fusion partners for TFEB (COL21A1 and CADM2). 
Schematic versions of these fusions show the exons 
and functional domains that are present in the different 
gene fusions and the position of potential microRNA 
binding sites in TFEB. The retained exons of TFE3 or 
TFEB are colored in shades of blue. Thin regions repre-
sent noncoding sequence, thick regions represent the 
translated reading frame, and white strips indicate that 
the region is no longer to scale. AD denotes strong 
transcription activation domain, bHLH basic helix-loop-
helix domain, DIX dishevelled and axin domain, LZ leu-
cine zipper domain, MAD2L2 mitotic arrest deficient–
like 2 interaction domain, and RRM RNA-recognition 
motif.
Figure 2. Alterations in Papillary Renal-Cell Carcinoma Involving the MET 
Oncogene.
Panel A is a schematic representation of somatic mutations in MET, along 
with germline variant H1112R, which was previously implicated in heredi-
tary papillary renal-cell carcinoma,17 and the novel RNA transcript variant 
of MET lacking the canonical exons 1 and 2 but containing a novel exon 1 
that splices to the canonical exon 3. IPT denotes immunoglobulin-like, plex-
ins, and transcription factors, and PSI plexins, semaphorins, and integrins. 
Panel B shows the crystal structure for the MET tyrosine kinase catalytic 
domain (RCSB-PDB 3I5 N18), on which are mapped the residues that are 
 altered in papillary renal-cell carcinoma. All numbering of amino acids is 
based on the MET protein sequences.
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(Fig. S6 in Supplementary Appendix 1). Dele-
tions of 1p36 co-occurred significantly with 
gain of chromosome 7 and EGFR amplification 
(P = 0.02 by Fisher’s exact test).
CDKN2A Mutation in Type 2 Tumors
Analysis by GISTIC, version 2.0, identified focal 
loss of 9p21 in 13 papillary renal-cell carcino-
mas (8.1%), resulting in loss of CDKN2A (Fig. S7A 
in Supplementary Appendix 1). We found muta-
tion or promoter hypermethylation of CDKN2A in 
11 tumors (Fig. S7B in Supplementary Appen-
dix 1), including 3 of the tumors with focal loss 
of 9p21, resulting in 21 tumors (13.0%) defined 
as having CDKN2A alteration (Fig. S7C in Supple-
mentary Appendix 1). CDKN2A alteration was 
strongly associated with type 2 histologic fea-
tures, with 25% of type 2 tumors (15 of 60) 
showing alterations. CDKN2A-altered tumors 
showed both increased levels of phosphorylated 
retinoblastoma protein (Rb) and increased ex-
pression of cell-cycle–related genes, findings 
consistent with the predicted consequences of 
CDKN2A loss (Fig. S7D in Supplementary Appen-
dix 1). In a univariate analysis, patients with 
CDKN2A-altered tumors had a significantly low-
er rate of overall survival than those without 
CDKN2A-altered tumors (P<1×10−10) (Fig. S7E in 
Supplementary Appendix 1). The findings were 
similar when the analysis was limited to patients 
with type 2 tumors (P<0.001) (Fig. S7F in Sup-
plementary Appendix 1). In addition, increased 
expression of microRNA miR-10b-5p correlated 
with decreased expression of its target, CDKN2A 
(Fig. S8 in Supplementary Appendix 1).
SETD2, BAP1, and PBRM1 Mutation in Type 2 
Tumors
Type 2 tumors were associated with mutations 
in the chromatin-modifying genes SETD2, BAP1, 
and PBRM1, which are frequently mutated in 
clear-cell kidney tumors in combination with 
loss of chromosome 3p.21 Mutations of BAP1 and 
PBRM1 were mutually exclusive, but PBRM1 muta-
tions were frequently concurrent with SETD2 
mutations (Fig. S9 in Supplementary Appendix 1). 
Although loss of chromosome 3p was also as-
sociated with type 2 papillary renal-cell carci-
noma, only 3 of 13 type 2 tumors with SETD2, 
BAP1, or PBRM1 mutation showed such loss, and 
no promoter hypermethylation was observed 
(Fig. S9 in Supplementary Appendix 1).
CpG Island Methylator Phenotype (CIMP) in Type 2 
Tumors
Nine tumors (5.6%) had increased DNA methyla-
tion at loci that were unmethylated in matched 
normal tissue. This represents a novel kidney-
associated CIMP22 that included universal hyper-
methylation of the CDKN2A promoter (Fig. 3A). 
Eight of the nine tumors were type 2 papillary 
renal-cell carcinomas. In five tumors, we found 
germline or somatic mutation of FH (56%). We 
found decreased expression of FH mRNA and 
increased expression of genes associated with 
cell-cycle progression and response to hypoxia 
in all nine tumors (Fig. 3A). Patients with CIMP-
associated tumors were younger at the time of 
presentation and had a lower probability of over-
all survival than other patients with papillary 
renal-cell carcinoma (Fig. 3B). Fumarate hydra-
tase–deficient type 2 tumors in patients with the 
hereditary leiomyomatosis and renal-cell cancer 
syndrome are characterized by a Warburg-like 
metabolic shift to glycolysis-dependent metabo-
lism and an increased expression of hypoxia-
related genes.25,26 Similarly, CIMP-associated tu-
mors showed increased expression of key genes 
involved in glycolysis (HK1, LDHA, and PDK1), the 
pentose phosphate pathway (G6PD), and fatty-acid 
synthesis (FASN) (Fig. 3C, and Fig. S10 in Supple-
mentary Appendix 1). In addition, there was 
decreased expression of the majority of genes 
involved in the Krebs cycle and the adenosine 
monophosphate–activated protein kinase (AMPK) 
complex, a suppressor of fatty-acid synthesis 
(Fig. 3D). Data on the expression of proteins 
G6PD, FASN, and AMPK correlated with the data 
on mRNA expression (Fig. 3D).
Identification of Papillary Renal-Cell 
Carcinoma Subgroups by Multiplatform Analysis
Cluster-of-Clusters Analysis
As was the case with the copy-number analysis 
and DNA-methylation analysis, the profiles of 
mRNA expression and microRNA expression 
and the data on protein expression clustered 
the cases of papillary renal-cell carcinoma into 
separate groups with distinct overall outcomes 
(Fig. S11, S12, and S13 in Supplementary Ap-
pendix 1). The five data types were combined 
to perform a cluster-of-clusters analysis27,28 that 
identified four tumor clusters: C1 (enriched for 
type 1 tumors), C2a and C2b (both enriched for 
type 2 tumors), and C2c (consisting solely of 
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Figure 3. A Subgroup of Papillary Renal-Cell Carcinoma That Manifests a CpG Island Methylator Phenotype (CIMP).
As depicted in Panel A, molecular subtyping by means of a DNA methylation platform revealed three subtypes of papillary renal-cell car-
cinoma (PRCC), one of which showed widespread DNA hypermethylation patterns characteristic of CIMP-associated tumors (the other 
subtypes are identified as cluster 1 and cluster 2). Corresponding data tracks highlight molecular features associated with CIMP tumors 
(nine cases), including CDKN2A silencing, germline or somatic mutations of FH, type 2 histologic status, and expression of both cell- 
cycle–related genes23 and hypoxia-related genes.24 Panel B shows differences in patient age and overall survival among the three sub-
types. Data on survival were not available for two patients in the cluster 2 group. Panel C shows differential messenger RNA (mRNA) 
 expression patterns for key genes involved in metabolism among CIMP-associated PRCC, type 1 PRCC, non–CIMP-associated type 2 
PRCC, and normal kidney. Panel D shows differential expression patterns of CIMP-associated tumors versus type 1 tumors in metabo-
lism-related pathways, with a focus on gene-expression and protein-expression patterns previously associated with Warburg-like effects 
in kidney cancer.21 P values were calculated with the use of a t-test.
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CIMP-associated papillary renal-cell carcinoma) 
(Fig. 4A).
Cluster C1 was predominantly type 1 papil-
lary renal-cell carcinoma and was strongly as-
sociated with gain of chromosome 7, MET muta-
tion, mRNA cluster 1, and an early stage of 
tumor development (stage I or II) (Fig. 4A, and 
Fig. S14 in Supplementary Appendix 1). Cluster 
C2a was predominantly type 2 papillary renal-
cell carcinoma and was associated with an early 
stage of tumor development and DNA methyla-
tion cluster 2. Cluster C2b consisted exclusively 
of type 2 and unclassified papillary renal-cell 
carcinomas and was associated with DNA meth-
ylation cluster 1, a later stage of tumor develop-
ment (stage III or IV), and mutation of SETD2. 
The CIMP-associated tumor subtype that was 
observed previously in DNA-methylation analysis 
was preserved as cluster C2c. Patients with clus-
ter C1 or cluster C2a tumors had the highest 
probability of overall survival, patients with 
cluster C2b tumors had a lower probability, and 
patients with cluster C2c tumors had the lowest 
probability (Fig. 4B).
NRF2-ARE Pathway in Type 2 Tumors
Pathway analysis was performed to compare the 
microRNA and mRNA signatures of type 1 tu-
mors with those of type 2 tumors (Fig. S15, S16, 
and S17 in Supplementary Appendix 1, and 
Supplementary Appendixes 7, 8, and 9), and data 
on mRNA expression highlighted the NRF2-ARE 
pathway as a distinguishing feature of type 2 
tumors (Fig. S17A in Supplementary Appendix 1). 
Expression of NQO1, a gene activated by the 
NRF2-ARE pathway,29 was lowest in cluster C1, 
intermediate in clusters C2a and C2b, and high-
est in the CIMP cluster C2c (P = 1×10−18 by analy-
sis of variance) (Fig. S18A in Supplementary 
Appendix 1), and increased NQO1 expression was 
associated with decreased survival (P = 0.001) 
(Fig. S18C in Supplementary Appendix 1). These 
findings are consistent with those of studies 
showing increased activation of the NRF2-ARE 
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Figure 4. Multiplatform-Based Subtype Discovery  
in Papillary Renal-Cell Carcinoma.
As shown in Panel A, integration of subtype classifica-
tions from five genomic data platforms with the use  
of a cluster-of-clusters analysis identified four major 
groups of papillary renal-cell carcinoma: C1 (enriched 
for type 1), C2a and C2b (enriched for type 2), and C2c 
(representing the CIMP-associated papillary renal-cell 
carcinomas). The heat map (center of panel) displays the 
subtypes defined independently by DNA methylation 
(pink), chromosomal copy number (black), microRNA 
expression (blue), mRNA expression (red), and protein 
(RPPA) expression (green); samples with missing data 
for protein expression are shown in gray. Clinical features 
associated with the multiplatform-based subtypes are 
also shown. Panel B shows differences in overall sur-
vival according to subtype. Data on survival were not 
available for two patients in the C1 group.
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pathway in type 2 tumors and mutations in 
NRF2-ARE pathway genes (NFE2L2, CUL3, KEAP1, 
and SIRT1).12,13 Four NFE2L2 (NRF2) mutations in 
known activating hotspots were identified, as 
well as mutations in both CUL3 (five mutations) 
and KEAP1 (one). These mutations in NFE2L2, 
CUL3, and KEAP1 correlated with high levels of 
NQO1 expression (P<1×10−6 by t-test) but did not 
solely account for the observed differences in 
NQO1 expression among subtypes (Fig. S18A in 
Supplementary Appendix 1).
Integrated Analysis of Low-Frequency 
Candidate Driver Mutations
Some tumors (most relatively small) lacked 
high-confidence candidate cancer-driving events. 
Manual pathway analysis identified candidate 
driver mutations in known cancer-associated 
genes, such as PTEN, NRAS, KRAS, TP53, TSC2, 
and those in the MLL and ARID families, in an 
additional 27% of the cases (Fig. S19A in Supple-
mentary Appendix 1, and Supplementary Appen-
dix 10). For the remaining 37 tumors (23%), 
low-frequency somatic events in genes identified 
by HotNet2 analysis (Fig. S19 in Supplementary 
Appendix 1) or associated with cancer in either 
the PanCan21 data set15 or the Catalogue of 
Somatic Mutations in Cancer database were pro-
posed as potential drivers and are listed in Sup-
plementary Appendix 10. In comparison with 
the tumors with candidate cancer-driving events, 
the remaining 37 papillary renal-cell carcinomas 
showed a higher percentage of type 1 tumors 
(26 of 37 [70%]) (P = 0.001 by Fisher’s exact test), 
and most (21 of 26 [81%]) showed a gain of 
chromosome 7, which includes MET. This gain 
of chromosome 7, which is seen in a number of 
tumors (e.g., Wilms’ tumor and papillary thy-
roid cancer), could be considered a driver event, 
but it does not identify a specific driver. Al-
though gain of chromosome 7 was associated 
with increased MET expression in papillary re-
nal-cell carcinoma (P<0.001 by two-factor analy-
sis of variance) (Fig. S20 in Supplementary 
Appendix 1), other potential driver genes on 
chromosome 7, such as EGFR, could influence 
tumorigenesis.
Discussion
We used a comprehensive genomics approach to 
characterize the biologic foundation of papillary 
renal-cell carcinoma and found that type 1 and 
type 2 papillary renal-cell carcinoma are dis-
tinctly different diseases and that type 2 papillary 
renal-cell carcinoma is a heterogeneous disease 
with multiple distinct subgroups. Common driver 
mutations among the different subtypes were 
relatively rare, as had been observed in two re-
cent studies.7,30 Molecular and phenotypic differ-
ences between type 1 and type 2 papillary renal-
cell carcinoma were reflected in individual and 
combined analyses of various data platforms. The 
usefulness of CDKN2A alterations as an indepen-
dent prognostic marker associated with type 2 
tumors requires validation. This study suggests 
that gene fusions involving TFE3 or TFEB are 
underappreciated in type 2 tumors in adults and 
should be considered in any patient with type 2 
disease. Although papillary renal-cell carcinomas 
with fusions involving TFE3 or TFEB are gener-
ally considered to be diseases of children and 
young adults,16 the mean age in our study was 
52 years, and we found tumors with TFEB fusions 
in patients 64 and 71 years of age.
The most distinct of the three type 2 sub-
groups was the subgroup defined by the CIMP, 
which was associated with the worst overall 
survival. CIMP hypermethylation patterns have 
been observed in a number of other cancer sub-
types, including glioblastoma,31 lung adenocar-
cinoma,32 and gastric adenocarcinoma.33 The 
CIMP-associated tumors showed low levels of FH 
mRNA expression, and five had germline or 
somatic mutation of FH. Germline mutation of 
FH has been observed in the aggressive type 2 
tumor associated with the hereditary leiomyoma-
tosis and renal-cell cancer syndrome.9,34 In this 
syndrome, the high levels of fumarate accumu-
lating from loss of fumarate hydratase enzyme 
activity result in impaired function of enzymes 
such as the TET family of enzymes, which play 
a role in maintaining appropriate DNA methyla-
tion within the genome.35 The subgrouping of 
type 2 tumors according to molecular features 
and the presence of specific subsets of type 2 
tumors, such as those with TFE3 fusions or 
CIMP, suggest that substratification of type 2 
papillary renal-cell carcinoma according to spe-
cific molecular markers may allow more accu-
rate diagnosis that could lead to the develop-
ment of mechanistic, disease-specific targeted 
therapies.
This classification of papillary renal-cell car-
cinoma could potentially have a substantial effect 
on clinical and therapeutic management and on 
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the design of clinical trials. Alteration of MET or 
gain of chromosome 7 was observed in a large 
percentage (81%) of type 1 tumors. Antitumor 
activity of an agent targeting the MET and 
VEGFR2 pathways has been shown in a phase 2 
trial involving patients with papillary renal-cell 
carcinoma, with a particularly high response 
rate among patients who had tumors with MET 
mutations.36 Mutation of the Hippo pathway tu-
mor suppressor, NF2, was observed in a number 
of papillary renal-cell carcinomas. This pathway 
has been targeted in other cancers with agents 
such as dasatinib, an inhibitor of the YES1 ki-
nase that interacts with the YAP transcription 
factor that is up-regulated with Hippo pathway 
dysregulation.37 The CIMP-associated tumors 
showed a Warburg-like metabolic shift, similar 
to that observed in fumarate hydratase–deficient 
tumors in patients with the hereditary leiomyo-
matosis and renal-cell cancer syndrome.11,25,26 A 
clinical trial targeting this metabolic shift in 
papillary renal-cell carcinoma is currently under 
way (ClinicalTrials.gov number, NCT01130519). 
Increased expression of the NRF2-ARE pathway 
has been observed in both hereditary and spo-
radic type 2 papillary renal-cell carcinomas.12 
Immunohistochemical analysis for NQO1 could 
provide a valuable marker of activation of the 
NRF2-ARE pathway. Currently, there is intense 
interest in the NRF2-ARE pathway in cancer,38 
and novel strategies have recently been devel-
oped to target this pathway.39
The identification of altered genes and path-
ways provides a comprehensive foundation for 
an understanding of the molecular basis of pap-
illary renal-cell carcinoma. This refined classifi-
cation more accurately reflects the genotypic 
and phenotypic differences among the various 
types of these tumors and may lead to more ap-
propriate clinical management and development 
of more effective forms of therapy.
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